Saturday, April 2, 2011

Abciximab

It is a chimeric (hybrid) monoclonal antibody.

Mechanism of action:
In this hybrid monoclonal antibody i.e. constant regions of human immunoglobulin and Fab fragments of murine monoclonal antibody gets bind to platelet GP IIb/IIIa receptos leading to blockage of the binding of fibrinogen and von Willebrand factor resulting in inhibition of aggregation.
Administration:

It is administered intravenously with aspirin and heparin.

Note: After stoppage of therapy platelet function gradually returns to normal.

Therapeutic uses:
It is used for the prevention of cardiac ischemia.

It is also recommended for patients with unstable angina.

Adverse effects:
It may cause bleeding disorders. Thrombocytopenia may also be caused.
Post a Comment